US FDA's Stein Outlines Functions Of Rare Disease, Inborn Error Groups In New OND Division

Office of New Drugs director Peter Stein shed some light on how the newly established Division of Rare Diseases and Medical Genetics will operate following the completion of the OND reorganization, drawing mixed reactions from industry speakers.